Carfilzomib Liver Toxicity Management

Introduction to Carfilzomib Liver Toxicity

Carfilzomib can cause liver function test elevations in approximately 13% of patients, and in rare cases may lead to acute liver failure, requiring careful monitoring and prompt discontinuation if significant hepatotoxicity develops 1

Liver function test (LFT) elevations of grade ≥3 occur in approximately 13% of patients receiving carfilzomib-based regimens, particularly when combined with lenalidomide and dexamethasone 2

Comprehensive cardiovascular and hepatic risk assessment should be performed before initiating carfilzomib therapy, according to the Journal of Internal Medicine 3, 4
Baseline liver function tests should be obtained, including ALT, AST, total bilirubin, and alkaline phosphatase, as recommended by the Journal of Internal Medicine 4
Identify and address modifiable risk factors that may contribute to liver dysfunction, including concomitant hepatotoxic medications, as suggested by the Journal of Internal Medicine 5, 6

Regular monitoring of liver function tests is essential during carfilzomib treatment, particularly during the first few cycles, according to the Journal of Internal Medicine 3, 4
Monitor for clinical signs and symptoms of hepatotoxicity, including jaundice 2, right upper quadrant pain 5, unexplained nausea or vomiting 7, fatigue 2

For grade 1-2 LFT elevations (≤5 × ULN), consider more frequent LFT assessment, as recommended by the Journal of the National Comprehensive Cancer Network 1
For grade 3 LFT elevations (>5-20 × ULN), consider temporary interruption of carfilzomib, evaluate for other potential causes, and resume at reduced dose when toxicity resolves to grade 1 or baseline, according to the Journal of Internal Medicine 7

Concomitant use of hepatotoxic medications is a risk factor for hepatotoxicity, as noted by the Journal of Internal Medicine 4
Advanced age is a risk factor for hepatotoxicity, as reported by the Journal of Internal Medicine 5
Prior liver disease or hepatic involvement by multiple myeloma is a risk factor for hepatotoxicity, according to the Journal of Internal Medicine 4

The risk-benefit ratio should be carefully evaluated in patients with pre-existing liver disease, as carfilzomib has demonstrated significant survival benefits in relapsed/refractory multiple myeloma, as noted by the Journal of Internal Medicine 7

Liver toxicity may be overlooked due to focus on more common carfilzomib-related adverse events such as cardiovascular toxicities, as warned by the Journal of Internal Medicine 3, 5